Perseo pharma AG

Perseo pharma is developing a complete new series of metabolic therapies based on its proprietary therapeutic enzymes platform, with much superior drug profiles, both in terms of efficacy and safety. Our first focus is on gastrointestinal applications, where patients are suffering from severe digestive deficiencies (Exocrine Pancreatic Insufficiency from pancreatitis, pancreatic cancer, cystic fibrosis, chemotherapy, infections) and must take pancreatic enzyme replacement therapies orally to improve their nutrition. We are engaged in a strategic partnership with Nestlé Health Science in this field. In parallel, we are developing a systemic version of our platform to address the large unmet medical need in enzyme replacement therapies.